本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
venBio Partners L.P. (CIK 1737053) reported $38.1M across 2 reported positions in its SEC 13F filing for 2018-12-31. Largest positions: ($23.6M, 62.01%), VRNA ($8.4M, 22.18%), VYNE ($6.0M, 15.82%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | Apellis Pharmaceuticals, Inc | $23.6M | 62.01% | 1.8M | Hold | |
| 2 | VRNA | Verona Pharma PLC | $8.4M | 22.18% | 875,000 | Hold |
| 3 | VYNE | Menlo Therapeutics Inc. | $6.0M | 15.82% | 1.5M | Hold |
来源：SEC 13F 申报文件 · 截至 2018-12-31